Why Did McKesson Buy U.S. Oncology?
This morning McKesson spent $2.16 billion today to buy U.Like this, you can set led light a mood or read a book or sew with great ease. Remember that lots of lighting sources are necessary within any room.S. Oncology–a physician practice management company for cancer doctors.
U.S.Ensuring that the low voltage downlight compact fluorescent fits in with the style and decor of the rest of the room is very important and in years gone by, this would not have been possible. Oncology went private in a $1.6 billion deal in 2006 led by the buyout firm Welsh Carson after new payment rules that affected how much the company could mark up cancer drugs required a retrenchment.
Looking quickly at its financial statements, the cancer practice has grown steadily since the buyout, from $2.8 billion to $3Countertops are areas where food preparation is often done. These are often illuminated with shallow supplyforyou fluorescent fixtures that are attached to the cabinet's underside..5 billion. Last year it earned $206 million in operating income. But because of it $1.6 billion in debt,Any type of muscle pain, stiffness is relieved deck lighting with the warm heat therapy from the traditional sauna. The heat from the sauna will increase blood flow to the joints and muscles too. Diabetic patients often have this problem with diabetic neuropathy in the feet and hands, so this is good for their circulation. on a net income-basis it lost $52 million.
Clearly McKesson thinks of itself as a strategic buyer.Now, we all know that a typical diode can output a very limited amount of light, so how does our Phillips chauvet dj lighting work? Well, it finds strength in numbers. It sells lots of medical equipment and drugs to doctors offices. It has a specialty pharmaceutical division, which it bought in 2007, that will now have a big customer plugged in as a subsidiary.
Jefferies analyst Richard Close likes the deal writing: “US Oncology currently distributes ~$2.4 billion worth of oncology pharmaceuticals annually, operates 83 comprehensive cancer centers, offers practice management services to practices, and has a network of ~1,300 affiliated physicians. Management estimates U.S. Oncology currently serves ~17% of all domestic cancer patients.” Close says the price was right at 9x earnings because it will strengthen McKesson’s speciality pharma division.
I have trouble, however, understanding the deal. Does it make sense to buy a practice of 1,300 doctors just for the privilege of selling their patients’ drugs? Is McKesson ready for the unique headaches associated with employing doctors and taking care of patients? With this deal San Francisco-based McKesson transforms from being a supplier of health care software, services, drugs and supplies–into an actual health care provider. What’s next? Will it buy hospitals so that it will have a guaranteed buyer of surgical kits and exam room paper? I watched a short video about the merger and am still confused.
Who loses in this deal? It might be bad news for AmerisourceBergen and Cardinal Health–the two other biggest providers of infused cancer drugs, according to Jefferies. Both will no longer have the opportunity to sell to U.S. Oncology practices.
This morning McKesson spent $2.16 billion today to buy U.Like this, you can set led light a mood or read a book or sew with great ease. Remember that lots of lighting sources are necessary within any room.S. Oncology–a physician practice management company for cancer doctors.
U.S.Ensuring that the low voltage downlight compact fluorescent fits in with the style and decor of the rest of the room is very important and in years gone by, this would not have been possible. Oncology went private in a $1.6 billion deal in 2006 led by the buyout firm Welsh Carson after new payment rules that affected how much the company could mark up cancer drugs required a retrenchment.
Looking quickly at its financial statements, the cancer practice has grown steadily since the buyout, from $2.8 billion to $3Countertops are areas where food preparation is often done. These are often illuminated with shallow supplyforyou fluorescent fixtures that are attached to the cabinet's underside..5 billion. Last year it earned $206 million in operating income. But because of it $1.6 billion in debt,Any type of muscle pain, stiffness is relieved deck lighting with the warm heat therapy from the traditional sauna. The heat from the sauna will increase blood flow to the joints and muscles too. Diabetic patients often have this problem with diabetic neuropathy in the feet and hands, so this is good for their circulation. on a net income-basis it lost $52 million.
Clearly McKesson thinks of itself as a strategic buyer.Now, we all know that a typical diode can output a very limited amount of light, so how does our Phillips chauvet dj lighting work? Well, it finds strength in numbers. It sells lots of medical equipment and drugs to doctors offices. It has a specialty pharmaceutical division, which it bought in 2007, that will now have a big customer plugged in as a subsidiary.
Jefferies analyst Richard Close likes the deal writing: “US Oncology currently distributes ~$2.4 billion worth of oncology pharmaceuticals annually, operates 83 comprehensive cancer centers, offers practice management services to practices, and has a network of ~1,300 affiliated physicians. Management estimates U.S. Oncology currently serves ~17% of all domestic cancer patients.” Close says the price was right at 9x earnings because it will strengthen McKesson’s speciality pharma division.
I have trouble, however, understanding the deal. Does it make sense to buy a practice of 1,300 doctors just for the privilege of selling their patients’ drugs? Is McKesson ready for the unique headaches associated with employing doctors and taking care of patients? With this deal San Francisco-based McKesson transforms from being a supplier of health care software, services, drugs and supplies–into an actual health care provider. What’s next? Will it buy hospitals so that it will have a guaranteed buyer of surgical kits and exam room paper? I watched a short video about the merger and am still confused.
Who loses in this deal? It might be bad news for AmerisourceBergen and Cardinal Health–the two other biggest providers of infused cancer drugs, according to Jefferies. Both will no longer have the opportunity to sell to U.S. Oncology practices.
沒有留言:
張貼留言